Related Experiment Video
Updated: Apr 23, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
Drug delivery: lessons to be learnt from Leishmania studies
1Strathclyde Institute of Pharmacy & Biomedical Sciences University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, Scotland, UK.
Background:
Leishmaniasis is a disease caused by infection with the protozoan parasite Leishmania, which is responsible for three main types of disease: cutaneous leishmaniasis, visceral leishmaniasis and mucocutaneous leishmaniasis based to the site of infection for the particular species. This presents a major challenge to successful drug treatment, as a drug must not only reach antileishmanial concentrations in infected macrophages, the parasites' host cell, but also reach infected cells in locations specific to the type of disease. In this paper we discuss how studies using Leishmania have contributed to our knowledge on how drug delivery systems can be used to improve drug efficacy and delivery.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Bioavailability Enhancement: Drug Permeability Enhancement
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Drug Delivery Systems: Different Types

